CANCERS BRONCHIQUES NON A PETITES CELLULES: Stades I-III réséqués
CHIMIOTHERAPIE ADJUVANTE


 Précédent Retour au menu principal  Suivant


référence

n

stades

bras contrôle

survie à 5 ans

bras adjuvant

survie à   5 ans

p

Holmes,

1986 (1)

130

II-III (68 pts)

BCG +

lévamisole

ND

CAP (62 pts)

ND

0,05

Lad,

1988 (2)

164

résection incomplète

RT (86 pts)

ND

RT+CAP (78 pts)

ND

NS

Niiranen,

1992 (3)

110

T1-3 N0

- (56 pts)

56 %

CAP (54 pts)

67 %

0,05

Feld,

1993 (4)

269

T1N1 ou T2 N0

- (133 pts)

ND

CAP (136 pts)

ND

NS

Ohta,

1993 (5)

181

IIIA

- (91 pts)

41 %

CDDP-VDS (90 pts)

35 %

NS

Dautzenberg,

1995 (6)

 

267
130
147

I,II,IIIA
 N0N1
 N2

RT (60  %) (129 pts)

19 %
34 %
 6 %

ADR/CPA-VCR-CDDP (138 pts)

18 %
17 %
19 %

NS
0,03

0,03

Chubu study,

1995 (7)

309

I – III

(III : 25%)

- (154 pts)

58 %

CDDP-ADR-UFT (155 pts)

62 %

NS

Wada,

1996 (8)

310

I – III

(III : 20 %)

 - (98 pts)

49 %

I. CDDP-VDS+UFT (109 pts)

61 %

 

 

0,05

II. UFT (103 pts)

64 %

Wada,

1999 (9)

226

I - II 

- (116 pts)

71,1 %

CDDP-MMC-VDS puis UFT (109 pts)

76,8 %

NS

Keller,

2000 (10)

488

II-IIIA

(IIIA : 58%)

RT (50,4 Gy) (242 pts)

ND

RT + CDDP-VP16 x 4 (246 pts)

ND

0,56

Mineo,

2002 (11)

66

IB (T2N0)

- (33pts)

45 %

CDDP + VP16 (33 pts)

63 %

0,04

Endo, ,

2003 (12)

221

T1-2 N0-1

- (110 pts)

75%

UFT 2 ans (109 pts)

79%

NS

Scagliotti,

2003 (13)

1209

I-IIIA

(IIIA : 28%)

(RT) (540 pts)

 

(RT) + CDDP-MMC-VDS x 3 (548 pts)

 

0,59

IALT,

2004 (14;15)

1867

I-III

(III : 39%)

RT (au choix du centre) (935pts)

40,4 %

CDDP + (au choix) VDS, VBL, VNR, VP16 (932 pts)

44,5 %

0,03

Puis

0,10

Tada,

2004(16)

119

pN2 résection complète

- (60 pts)

36,1 %

CDDP-VDS x 3 (59 pts)

28,2 %

0,89

Kato,

2004 (17)

980

I (adénoc)

- (488pts)

85 %

UFT (491pts)

88 %

0,047

Ueda,

2004

30

I – III

(IIIA : 10%)

- (13pts)

61 %

UFT (17 pts)

93 %

0,046

Waller,

2004 (18)

381

I-III

- (RT) (189 pts)

 

à base de cisplatine (+/- RT)

 

0.90

Nakagawa,

2005 (19)

332

I

- (169 pts)

76 %

UFT (163 pts)

82 %

0,10

Winton,

2005 (20;21)

482

IB-II

- (240 pts)

54 %

CDDP + VNR (242 pts)

69 %

0,04

Imaizumi,

2005 (22)

150

I

- (50 pts)

66,3 %

CDDP + VDS + UFT (50 pts)

87,9 %

0,045

UFT (50 pts)

67,7 %

Douillard,

2006 (23)

840

IB-IIIA

- (433 pts)

 

CDDP-VNR

+ 8,6%

0,017

Strauus,

2008(24)

344

IB

- (171 pts)

58 %

Paclitaxel + carboplatine (173 pts)

60 %

NS

Ou,

2010 (25)  A

150

IIIAN2

- (71pts)

31 %

Carboplatine + VNR ou PAC (79 pts)

19 %

S


Références
(1) Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986 May;4(5):710-5.
(2) Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node (stage IIIA). LCSG 791. Chest 1994 Dec;106(6 Suppl):302S-6S.
(3) Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhonen S. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 1992 Dec;10(12):1927-32.
(4) Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 1993 Feb 17;85(4):299-306.
(5) Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993 Oct;106(4):703-8.
(6) Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 1995 Sep 1;76(5):779-86.
(7) A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol 1995 Feb;21(1):69-77.
(8) Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery [see comments]. J Clin Oncol 1996 Apr;14(4):1048-54.
(9) Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999 Apr;15(4):438-43.
(10) Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, et al. A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer. N Engl J Med 2000 Oct 26;343(17):1217-22.
(11) Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001 Aug;20(2):378-84.
(12) Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003 May;40(2):181-6.
(13) Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003 Oct 1;95(19):1453-61.
(14) Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004 Jan 22;350(4):351-60.
(15) Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010 Jan 1;28(1):35-42.
(16) Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004 Feb;43(2):167-73.
(17) Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004 Apr 22;350(17):1713-21.
(18) Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004 Jul;26(1):173-82.
(19) Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. Ann Oncol 2005 Jan;16(1):75-80.
(20) Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005 Jun 23;352(25):2589-97.
(21) Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010 Jan 1;28(1):29-34.
(22) Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 2005 Jul;49(1):85-94.
(23) Douillard JY, Rosell R, De LM, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006 Sep;7(9):719-27.
(24) Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008 Nov 1;26(31):5043-51.
(25) Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, et al. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer. J Thorac Oncol 2010 Jul;5(7):1033-41.




Retour au début de la page